Janssen Pharmaceutical Unlimited Company, a subsidiary of Johnson & Johnson, is a leading player in the global pharmaceutical industry, headquartered in Ireland (IE). Founded in 1953, the company has established a strong presence in key operational regions, including Europe, North America, and Asia, focusing on innovative solutions across various therapeutic areas such as oncology, immunology, and neuroscience. Renowned for its commitment to research and development, Janssen offers a diverse portfolio of core products, including groundbreaking treatments that address unmet medical needs. The company has achieved notable milestones, including the development of several blockbuster drugs that have significantly impacted patient care. With a strong market position, Janssen continues to be recognised for its contributions to healthcare, driving advancements that enhance the quality of life for patients worldwide.
How does Janssen Pharmaceutical Unlimited Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Janssen Pharmaceutical Unlimited Company's score of 51 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Janssen Pharmaceutical Unlimited Company, headquartered in Ireland (IE), currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. In the absence of specific emissions data, it is important to note that many pharmaceutical companies are increasingly focusing on sustainability and climate commitments. This often includes setting science-based targets for reducing greenhouse gas emissions across all scopes (Scope 1, 2, and 3) and implementing initiatives aimed at minimising their environmental impact. As the industry evolves, it is expected that Janssen Pharmaceutical will align with these trends, potentially adopting ambitious climate strategies in the future.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Janssen Pharmaceutical Unlimited Company is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.